Patents by Inventor Noam Shani
Noam Shani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897937Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: GrantFiled: August 12, 2021Date of Patent: February 13, 2024Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20240010700Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: June 21, 2023Publication date: January 11, 2024Applicant: KAHR Medical Ltd.Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11702458Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: July 18, 2023Assignee: KAHR Medical Ltd.Inventors: Mark L. Tykocinski, Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20230220040Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: January 26, 2023Publication date: July 13, 2023Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11566060Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: January 31, 2023Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20220204586Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: March 16, 2022Publication date: June 30, 2022Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11299530Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: April 12, 2022Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20210371500Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: August 12, 2021Publication date: December 2, 2021Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11130796Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: September 28, 2021Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20190352371Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: November 21, 2019Applicant: KAHR Medical Ltd.Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20190352372Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: November 21, 2019Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20190330304Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: October 31, 2019Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20190315834Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: October 17, 2019Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
STABLE FORM OF SIGNAL CONVERTING PROTEIN FUSION PROTEINS, AND METHODS OF USE AND PREPARATION THEREOF
Publication number: 20190016782Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.Type: ApplicationFiled: July 5, 2018Publication date: January 17, 2019Applicant: KAHR Medical Ltd.Inventors: Michal DRANITZKI ELHALEL, Noam SHANI -
Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
Patent number: 10040841Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.Type: GrantFiled: December 31, 2013Date of Patent: August 7, 2018Assignee: KAHR Medical Ltd.Inventors: Michal Dranitzki Elhalel, Noam Shani -
Publication number: 20180169183Abstract: The invention provides a composition and use of a composition comprising a fusion protein and a first ligand in a ratio sufficient to increase therapeutic efficacy of the fusion protein in a subject, the fusion protein comprising an extracellular domain (ECD) of a first receptor and a second ligand, wherein the second ligand is capable of binding to a second receptor, wherein the first ligand is capable of binding to the first receptor, wherein the first and second ligands, and the first and second receptors, are TNF-family members, and wherein the first and second ligands are different, and the first and second receptors are different. The invention also provides a composition comprising Fn14-TRAIL fusion protein and TWEAK and use thereof for treating diseases or conditions associated with increased levels of TWEAK. The invention is further directed to use of Fn14-TRAIL fusion protein to treat diseases or conditions associated with increased levels of TWEAK.Type: ApplicationFiled: March 3, 2016Publication date: June 21, 2018Applicant: KAHR MEDICAL LTDInventors: Michal DRANITZKI ELHALEL, Noam SHANI
-
Patent number: 9468667Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: June 30, 2013Date of Patent: October 18, 2016Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Stable Form Of Signal Converting Protein Fusion Proteins, And Methods Of Use And Preparation Thereof
Publication number: 20150376260Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.Type: ApplicationFiled: December 31, 2013Publication date: December 31, 2015Applicant: KAHR MEDICAL LTD.Inventors: Michal Dranitzki ELHALEL, Noam SHANI -
Publication number: 20150313623Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: ApplicationFiled: July 8, 2015Publication date: November 5, 2015Applicant: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Patent number: 9107896Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: February 9, 2012Date of Patent: August 18, 2015Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon